Q1 2026 West Pharmaceutical Services Inc Earnings Call Transcript
Key Points
- West Pharmaceutical Services Inc (WST) reported a strong start to the year with first-quarter revenues of $845 million, up 21% on a reported basis and 15% on an organic basis.
- Adjusted EPS increased by 47% compared to the prior year, reaching $2.13.
- The company raised its full-year revenue and adjusted EPS guidance, anticipating organic revenue growth of 7% to 9% and adjusted EPS between $8.40 to $8.75.
- HVP components, a key growth driver, grew 23% on an organic basis, with strong performance in both GLP-1 and non-GLP-1 revenues.
- Biologics delivered 26% organic growth, driven by strong win rates and easing regulations, contributing significantly to the company's performance.
- Despite strong performance, the macro environment remains dynamic, requiring prudent forecasting for the rest of the year.
- The company faces increased costs due to rising oil and commodity prices, although mitigation efforts are in place.
- The divestiture of SmartDose 3.5 is expected to impact revenue in the second half of the year.
- The operational excellence initiative, while beneficial, requires ongoing efforts to optimize global manufacturing and leverage existing capacity.
- The transition of the CGM contract in Dublin may create a temporary revenue dip in the West Vantage segment in the second half of the year.
Good day, and welcome to West's first-quarter earnings conference call.
(Operator Instructions)
Please note today's call is being recorded. I would now like to turn the call over to John Sweeney, Vice President of Investor Relations. Please go ahead.
Good morning, and welcome to West's first-quarter 2026 earnings conference call, which has been webcast live. With me today on the call are West's President, CEO and Chairman, Eric Green, and West's Senior Vice President and CFO, Bob McMahon. Earlier today, we issued our first-quarter financial results.
A copy of the press release, along with today's slide presentation containing supplemental information for your reference has been posted in the Investors section of the company's website at investor.westpharma.com. Later today, a replay of the webcast will also be available in the Investors section of our website.
Before we begin, we'd like to remind you that statements made by management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
